Macroscopic and microscopic features of surgically explanted transcatheter aortic valve prostheses.
TAVR valve explantation
leaflet damage
structural valve degeneration
surgical aortic valve replacement
transcatheter aortic valve explantation
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
12
06
2022
received:
09
04
2022
accepted:
19
06
2022
pubmed:
24
7
2022
medline:
8
9
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
With the extended indications of transcatheter aortic valve (TAV) replacement (TAVR) to lower-risk patients, there is an increasing number of patients requiring surgical explantation of failed TAV. We sought to describe macroscopic and microscopic features of surgically explanted percutaneous aortic valve prostheses. Preoperative and surgical characteristic of patients undergoing surgical explantation of TAV were retrospectively analyzed from 2007 to 2020. Surgical and pathologic features of these valves, and outcomes of the surgical valve replacement were described. Out of 1764 patients who underwent a TAVR procedure, 21 were operated for TAV failure. Isolated or combined indications for surgery included: significant paravalvular leak (n = 15), delayed prosthesis migration (n = 5), significant increase of trans-TAV gradients (n = 6), and endocarditis (n = 3). Mean time elapsed between TAVR and explantations was 674.9 ± 803.9 days. Macroscopic lesions found on explanted percutaneous valves were severe adhesions to the aorta (n = 10), calcifications (n = 7), leaflet thrombosis (n = 4), and vegetations (n = 3). Except for patients with endocarditis, one or more pathological lesions were found in 15 patients. Pathology analyses on these valves showed fibro-calcific degenerations (n = 12), pannus formation (n = 9), and chronic inflammation (n = 3). One patient (4.8%) died after surgical explantation, and 13 (61.9%) had concomitant procedures. The survival rate at 1 year was 94.4%. Microscopic findings of fibro-calcific leaflet degeneration, and pannus formation in addition to macroscopic calcification and thrombosis present early, (within a mean of 2 years) after TAVR. Further investigation with a higher number of patients and echocardiographic follow-up is warranted.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3178-3187Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2018;2017(38):2739-2791.
Cribier A. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006-3008.
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:363-1607.
Mack MJ, Leon MB, Smith CR, et al. Five-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. The Lancet. 2015;385:2477-2484.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-1620.
Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. The Lancet. 2016;387:2218-2225.
Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321-1331.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:380-1715.
Warren BA, Yong JL. Calcification of the aortic valve: its progression and grading. Pathology. 1997;29:360-368.
Liesman DR, Fukuhara S. Leaflet perforation or tear late after transcatheter aortic valve implantation. J Thorac Cardiovasc Surg Tech. 2020;3:3-94.
Linke A, Höllriegel R, Walther T, et al. Ingrowths of a percutaneously implanted aortic valve prosthesis (corevalve) in a patient with severe aortic stenosis. Circ Cardiovasc Interv. 2008;1:155-158.
Nietlispach F, Webb JG, Ye J, et al. Pathology of transcatheter valve therapy. JACC Cardiovasc Interv. 2012;5:582-590.
Belhaj Soulami R, Anselmi A, Tomasi J, Verhoye JP. Late surgical explantation of a transcatheter heart valve in a patient with a porcelain aorta. Eur J Cardiothorac Surg. 2019;55:1008-1011.
Wang LW, Granger EK, McCourt JA, Pye R, Kaplan JM, Muller DW. Late surgical explantation and aortic valve replacement after transcatheter aortic valve implantation. Ann Thorac Surg. 2015;99:1434-1436.
Marti D, Rubio M, Escribano N, de Miguel R, Rada I, Moris C. Very late thrombosis of a transcatheter aortic valve-in-valve. JACC Cardiovasc Interv. 2015;8:e151-e153.
Fukuhara S, Tanaka D, Brescia AA, et al. Aortic valve reintervention in patients with failing transcatheter aortic bioprostheses: a statewide experience. J Thorac Cardiovasc Surg. 2021. doi:10.1016/j.jtcvs.2021.08.057
Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, et al. Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation. 2015;131:1566-1574.
Mangi AA, Ramchandani M, Reardon M. Surgical removal and replacement of chronically implanted transcatheter aortic prostheses: how I teach it. Ann Thorac Surg. 2018;105:12-14.
Malvindi PG, Luthra S, Sarvananthan S, Zingale A, Olevano C, Ohri S. Surgical treatment of transcatheter aortic valve infective endocarditis. Neth Heart J. 2020;29:71-77.
Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015-2024.
Notaristefano F, Reccia MR, Notaristefano S, et al. Bailout surgical explantation of a transcatheter valve-in-valve for subacute thrombosis: when there is no time for anticoagulation: case report and literature review. Cardiovasc Revasc Med. 2018;19:536-539.
De Marchena E, Mesa J, Pomenti S, et al. Thrombus formation following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2015;8:728-739.
Liesman DR, Fukuhara S. Leaflet perforation or tear late after transcatheter aortic valve implantation. J Thorac Cardiovasc Surg Tech. 2020;3:92-94.
Ribeiro HB, Nombela-Franco L, Urena M, et al. Coronary obstruction following transcatheter aortic valve implantation: a systematic review. JACC Cardiovasc Interv. 2013;6:452-461.
Bloom JP, Kwon MH, Tolis G, Jr. Early distal migration of a self-expanding aortic valve prosthesis causing myocardial infarction. Ann Thorac Surg. 2019;108:e1-e3.
Hirji SA, Percy ED, McGurk S, et al. Incidence, characteristics, predictors, and outcomes of surgical explantation after transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76:1848-1859.
Fukuhara S, Brescia AA, Shiomi S, et al. Surgical explantation of transcatheter aortic bioprostheses: balloon vs self-expandable devices. Ann Thorac Surg. 2021;162:539-547.e1.
Jawitz OK, Gulack BC, Grau-Sepulveda MV, et al. Reoperation after transcatheter aortic valve replacement: an analysis of the Society of Thoracic Surgeons Database. JACC Cardiovasc Interv. 2020;13:1515-1525.
Lehmann S, Jawad K, Dieterlen MT, et al. Durability and clinical experience using a bovine pericardial prosthetic aortic valve. J Thorac Cardiovasc Surg. 2021;161:1742-1749.
Percy ED, Harloff M, Hirji S, et al. Subclinical structural valve degeneration in young patients with bioprosthetic aortic valves. Ann Thorac Surg. 2021;111:1486-1493.
Rodriguez-Gabella T, Voisine P, Dagenais F, et al. Long-term outcomes following surgical aortic bioprosthesis implantation. J Am Coll Cardiol. 2018;71:1401-1412.
Salaun E, Mahjoub H, Dahou A, et al. Hemodynamic deterioration of surgically implanted bioprosthetic aortic valves. J Am Coll Cardiol. 2018;72:241-251.
Balmforth D, Dimagli A, Benedetto U, Uppal R. Fifty years of the pericardial valve: long-term results in the aortic position. J Card Surg. 2021;36:2865-2875.
Salaun E, Mahjoub H, Girerd N, et al. Rate, timing, correlates, and outcomes of hemodynamic valve deterioration after bioprosthetic surgical aortic valve replacement. Circulation. 2018;138:971-985.
Kostyunin AE, Yuzhalin AE, Rezvova MA, Ovcharenko EA, Glushkova TV, Kutikhin AG. Degeneration of bioprosthetic heart valves: update 2020. J Am Heart Assoc. 2020;9:e018506.
Yanagawa B, Mazine A, Bhatt DL, et al. Subclinical bioprosthetic aortic valve thrombosis: clinical and translational implications. Curr Opin Cardiol. 2017;32:137-146.
Fukuhara S, Brescia AA, Shiomi S, et al. Surgical explantation of transcatheter aortic bioprostheses: results and clinical implications. J Thorac Cardiovasc Surg. 2020;162:539-547.
Park H, Leung Wai Sang S, Merhi WM. Extremely early structural failure of a self-expanding transcatheter aortic valve secondary to leaflet dehiscence. JTCVS Techniques. 2020;3:87-88.
Alavi SH, Groves EM, Kheradvar A. The effects of transcatheter valve crimping on pericardial leaflets. Ann Thorac Surg. 2014;97:1260-1266.
Ferreira-Neto AN, Rodriguez-Gabella T, Guimaraes L, et al. Multimodality evaluation of transcatheter structural valve degeneration at long-term follow-up. Rev Esp Cardiol. 2021;74:247-256.